Skip to main content
Journal cover image

Vericiguat for the treatment of heart failure with reduced ejection fraction.

Publication ,  Journal Article
Siddiqi, AK; Greene, SJ; Fudim, M; Mentz, RJ; Butler, J; Khan, MS
Published in: Expert Rev Cardiovasc Ther
April 2023

INTRODUCTION: Despite significant therapeutic advancements in heart failure with reduced ejection fraction (HFrEF), the residual risk of all-cause mortality and hospitalizations remains high among patients with HFrEF. Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator which was approved by the US Food and Drug administration (FDA) in January 2021 for use in patients with symptomatic chronic HF and an ejection fraction less than 45% following a hospitalization for HF or the need for outpatient intravenous diuretics. AREAS COVERED: We provide a concise review of the pharmacology, clinical efficacy, and tolerability of vericiguat in HFrEF. We also discuss the role of vericiguat in current clinical practice. EXPERT OPINION: Vericiguat reduces the risk of cardiovascular mortality or HF hospitalizations by an absolute event-rate reduction of 4.2 events per 100 patient-years with a number needed to treat of 24 patients, on a background of guideline-directed medical therapy. Almost 90% of the patients with HFrEF were adherent to the 10 mg dose of vericiguat in the VICTORIA trial with a favorable tolerability and safety profile. Considering the high residual risk that persists in HFrEF, vericiguat has a role to improve outcomes among patients with worsening HFrEF.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Cardiovasc Ther

DOI

EISSN

1744-8344

Publication Date

April 2023

Volume

21

Issue

4

Start / End Page

245 / 257

Location

England

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Treatment Outcome
  • Stroke Volume
  • Humans
  • Heterocyclic Compounds, 2-Ring
  • Heart Failure
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Siddiqi, A. K., Greene, S. J., Fudim, M., Mentz, R. J., Butler, J., & Khan, M. S. (2023). Vericiguat for the treatment of heart failure with reduced ejection fraction. Expert Rev Cardiovasc Ther, 21(4), 245–257. https://doi.org/10.1080/14779072.2023.2189101
Siddiqi, Ahmed K., Stephen J. Greene, Marat Fudim, Robert J. Mentz, Javed Butler, and Muhammad Shahzeb Khan. “Vericiguat for the treatment of heart failure with reduced ejection fraction.Expert Rev Cardiovasc Ther 21, no. 4 (April 2023): 245–57. https://doi.org/10.1080/14779072.2023.2189101.
Siddiqi AK, Greene SJ, Fudim M, Mentz RJ, Butler J, Khan MS. Vericiguat for the treatment of heart failure with reduced ejection fraction. Expert Rev Cardiovasc Ther. 2023 Apr;21(4):245–57.
Siddiqi, Ahmed K., et al. “Vericiguat for the treatment of heart failure with reduced ejection fraction.Expert Rev Cardiovasc Ther, vol. 21, no. 4, Apr. 2023, pp. 245–57. Pubmed, doi:10.1080/14779072.2023.2189101.
Siddiqi AK, Greene SJ, Fudim M, Mentz RJ, Butler J, Khan MS. Vericiguat for the treatment of heart failure with reduced ejection fraction. Expert Rev Cardiovasc Ther. 2023 Apr;21(4):245–257.
Journal cover image

Published In

Expert Rev Cardiovasc Ther

DOI

EISSN

1744-8344

Publication Date

April 2023

Volume

21

Issue

4

Start / End Page

245 / 257

Location

England

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Treatment Outcome
  • Stroke Volume
  • Humans
  • Heterocyclic Compounds, 2-Ring
  • Heart Failure
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology